> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-64/
- Published: 2022-01-09T12:00:00.000Z
- Updated: 2026-09-14T17:27:58.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150489

**Public Meeting on Generic Drug User Fees**  
1/7/2022 *Federal Register* notice: FDA has announced an 2/16 public meeting to discuss proposed recommendations for the reauthorization of the Generic Drug User Fee Amendments for fiscal years 2023 through 2027\. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-10-29/pdf/2021-23499.pdf?ref=fdaweb.com).

**4 Information Collections Approved by OMB**  
1/6/2022 *Federal Register* notice: FDA is publishing a list of information collections that have been approved by OMB. They are:

- Infant Formula Requirements
- Shortages Data Collection
- Guidance on Labeling for Natural Rubber Latex Condoms
- Section 513(g) Requests for Information

To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-10-28/pdf/2021-23504.pdf?ref=fdaweb.com).

**Enzyvant Wins Priority Review Voucher**  
1/6/2022 *Federal Register* notice: FDA has issued a priority review voucher to Enzyvant Therapeutics in response to its approval of a qualified rare pediatric disease product application. The agency determined that the company’s Rethymic (allogeneic processed thymus tissue-agdc), indicated for immune reconstitution in pediatric patients with congenital athymia, meets the criteria for a priority review voucher. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23336.pdf?ref=fdaweb.com).

**Panel to Review Merck Covid Drug**  
1/5/2022 *Federal Register* notice: FDA has announced an 1/30 Antimicrobial Drugs Advisory Committee meeting to review a Merck Emergency Use Authorization request for molnupiravir oral capsules, indicated for treating mild to moderate Covid-19 in adults who are at risk for progressing to severe disease or hospitalization. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23384.pdf?ref=fdaweb.com).

**CDRH Guidance Document Plans for FY 2022**  
1/4/2022 *Federal Register* notice: FDA is announcing the [Web site location](https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/cdrh-proposed-guidance-development?ref=fdaweb.com) where it will post two lists of guidance documents that CDRH intends to publish in fiscal year 2022\. In addition, FDA has established a docket where interested persons may comment on topic priorities. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23392.pdf?ref=fdaweb.com).